These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20969873)

  • 1. Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design.
    Correia BE; Ban YE; Friend DJ; Ellingson K; Xu H; Boni E; Bradley-Hewitt T; Bruhn-Johannsen JF; Stamatatos L; Strong RK; Schief WR
    J Mol Biol; 2011 Jan; 405(1):284-97. PubMed ID: 20969873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope.
    Azoitei ML; Ban YE; Julien JP; Bryson S; Schroeter A; Kalyuzhniy O; Porter JR; Adachi Y; Baker D; Pai EF; Schief WR
    J Mol Biol; 2012 Jan; 415(1):175-92. PubMed ID: 22061265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope.
    Correia BE; Ban YE; Holmes MA; Xu H; Ellingson K; Kraft Z; Carrico C; Boni E; Sather DN; Zenobia C; Burke KY; Bradley-Hewitt T; Bruhn-Johannsen JF; Kalyuzhniy O; Baker D; Strong RK; Stamatatos L; Schief WR
    Structure; 2010 Sep; 18(9):1116-26. PubMed ID: 20826338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.
    Azoitei ML; Ban YA; Kalyuzhny O; Guenaga J; Schroeter A; Porter J; Wyatt R; Schief WR
    Proteins; 2014 Oct; 82(10):2770-82. PubMed ID: 25043744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10.
    Cardoso RM; Brunel FM; Ferguson S; Zwick M; Burton DR; Dawson PE; Wilson IA
    J Mol Biol; 2007 Feb; 365(5):1533-44. PubMed ID: 17125793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice.
    Yi G; Tu X; Bharaj P; Guo H; Zhang J; Shankar P; Manjunath N
    Mol Ther; 2015 Oct; 23(10):1663-70. PubMed ID: 26061648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.
    Ching L; Stamatatos L
    J Virol; 2010 Oct; 84(19):9932-46. PubMed ID: 20660181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41.
    Dong XN; Xiao Y; Chen YH
    Immunol Lett; 2001 Jan; 75(2):149-52. PubMed ID: 11137140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.
    Brunel FM; Zwick MB; Cardoso RM; Nelson JD; Wilson IA; Burton DR; Dawson PE
    J Virol; 2006 Feb; 80(4):1680-7. PubMed ID: 16439525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.
    Li J; Chen X; Jiang S; Chen YH
    Biochem Biophys Res Commun; 2008 Nov; 376(1):60-4. PubMed ID: 18762167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial protein vaccines with predetermined tertiary structure: application to anti-HIV-1 vaccine design.
    Eroshkin AM; Zhilkin PA; Shamin VV; Korolev S; Fedorov BB
    Protein Eng; 1993 Nov; 6(8):997-1001. PubMed ID: 7508628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine.
    Wahome N; Pfeiffer T; Ambiel I; Yang Y; Keppler OT; Bosch V; Burkhard P
    Chem Biol Drug Des; 2012 Sep; 80(3):349-57. PubMed ID: 22650354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.
    Morales JF; Yu B; Perez G; Mesa KA; Alexander DL; Berman PW
    Mol Immunol; 2016 Sep; 77():14-25. PubMed ID: 27449907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold.
    Azoitei ML; Correia BE; Ban YE; Carrico C; Kalyuzhniy O; Chen L; Schroeter A; Huang PS; McLellan JS; Kwong PD; Baker D; Strong RK; Schief WR
    Science; 2011 Oct; 334(6054):373-6. PubMed ID: 22021856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy.
    Law M; Cardoso RM; Wilson IA; Burton DR
    J Virol; 2007 Apr; 81(8):4272-85. PubMed ID: 17267498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.
    Eckhart L; Raffelsberger W; Ferko B; Klima A; Purtscher M; Katinger H; Rüker F
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2001-8. PubMed ID: 8810996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of high levels of antibodies recognizing the neutralizing epitope ELDKWA and the D- or K-position-mutated epitopes by candidate epitope vaccines against HIV-1.
    Xiao Y; Dong X; Chen Y
    Int Arch Allergy Immunol; 2000 Aug; 122(4):287-92. PubMed ID: 10971120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure of the HIV-1 broadly neutralizing antibody 10E8 MPER epitope on the membrane surface by gp41 transmembrane domain scaffolds.
    Oakes V; Torralba J; Rujas E; Nieva JL; Domene C; Apellaniz B
    Biochim Biophys Acta Biomembr; 2018 Jun; 1860(6):1259-1271. PubMed ID: 29477358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.